Amphastar reported a slight decline in Q4 revenue to $183.1 million, primarily due to lower sales of Glucagon and Epinephrine, which were partially offset by a 12% increase in BAQSIMI® sales. Despite the revenue dip, the company maintained a strong gross margin of 46.8% and continued to invest heavily in its R&D pipeline, particularly in insulin and inhalation products.

Amphastar Pharmaceuticals reported net revenues of $170.5 million for the first quarter of 2025, a slight decrease from the previous year, with GAAP net income of $25.3 million and adjusted non-GAAP net income of $36.9 million. The company highlighted strong growth in BAQSIMI® and Primatene MIST® sales, alongside progress in its biosimilar pipeline.

Amphastar Pharmaceuticals reported strong financial results for the fourth quarter of 2024, with net revenues increasing to $186.5 million and GAAP net income reaching $38.0 million. The company also exceeded its long-term goal for Primatene MIST® annual sales and saw significant growth in BAQSIMI® factory sales.

Amphastar Pharmaceuticals reported a net revenue increase of 6% to $191.2 million for the third quarter of 2024. GAAP net income was $40.4 million, and adjusted non-GAAP net income reached $49.6 million. The company's growth was driven by sales, particularly from BAQSIMI® and Primatene MIST®.

Amphastar Pharmaceuticals reported a strong second quarter with net revenues of $182.4 million, a 25% increase compared to the same period last year. GAAP net income was $37.9 million, or $0.73 per share, while adjusted non-GAAP net income reached $48.7 million, or $0.94 per share. The company's performance was driven by solid sales growth, particularly with BAQSIMI®.

Amphastar Pharmaceuticals reported net revenues of $171.8 million for the three months ended March 31, 2024, a 23% increase compared to the same period in 2023. GAAP net income was $43.2 million, or $0.81 per share, while adjusted non-GAAP net income was $55.3 million, or $1.04 per share.

Amphastar Pharmaceuticals reported a strong fourth quarter with net revenues of $178.1 million and GAAP net income of $36.2 million, driven by glucagon and Primatene MIST® performance and the acquisition of BAQSIMI®.

Amphastar Pharmaceuticals reported net revenues of $180.6 million for the three months ended September 30, 2023. GAAP net income was $49.2 million, or $0.91 per share, and adjusted non-GAAP net income was $61.9 million, or $1.15 per share.

Amphastar Pharmaceuticals reported a strong second quarter with net revenues of $145.7 million and GAAP net income of $26.1 million, driven by glucagon and phytonadione sales growth and contributions from newer products. The acquisition of BAQSIMI® on June 30 is expected to further strengthen the company's proprietary products profile.

Amphastar Pharmaceuticals reported a strong first quarter in 2023, with net revenues reaching $140.0 million, a 16% increase compared to Q1 2022. GAAP net income rose to $26.0 million, or $0.50 per share, and adjusted non-GAAP net income was $32.1 million, or $0.62 per share. The company's growth was primarily fueled by increased sales of glucagon, Primatene MIST®, and epinephrine.

Amphastar Pharmaceuticals reported its strongest quarter yet, with net revenues of $135.0 million, GAAP net income of $33.9 million, or $0.66 per share, and adjusted non-GAAP net income of $37.6 million, or $0.73 per share, driven by sales of epinephrine, Primatene MIST®, glucagon, and other finished pharmaceutical products.

Amphastar Pharmaceuticals reported net revenues of $120.1 million for Q3 2022, a 7% increase compared to Q3 2021. GAAP net income was $15.9 million, or $0.30 per share, while adjusted non-GAAP net income was $20.2 million, or $0.38 per share. The company's growth was primarily driven by strong sales of epinephrine, Primatene Mist®, and glucagon.

Amphastar Pharmaceuticals reported strong sales for the second quarter of 2022, with net revenues reaching $123.5 million and GAAP net income of $17.3 million, or $0.33 per share. Adjusted non-GAAP net income was $20.7 million, or $0.39 per share.

Amphastar Pharmaceuticals reported a strong first quarter with net revenues of $120.4 million and a GAAP net income of $24.3 million, driven by strong sales of recently launched products.

Amphastar Pharmaceuticals reported strong Q4 2021 results, with net revenues reaching $120.9 million and a GAAP net income of $19.8 million, driven by the growth of higher-margin products.

Amphastar Pharmaceuticals reported a strong third quarter with net revenues of $112.2 million, a 34% increase compared to the same period last year. GAAP net income was $29.5 million, or $0.59 per share, while adjusted non-GAAP net income was $23.0 million, or $0.46 per share.

Amphastar Pharmaceuticals reported a strong second quarter with net revenues of $101.7 million and a GAAP net income of $7.8 million, driven by strong sales of glucagon, Primatene Mist, and epinephrine products.

Amphastar Pharmaceuticals reported a strong first quarter with net revenues of $103.0 million, driven by the launch of glucagon and increased sales of Primatene Mist and epinephrine products. GAAP net income was $5.0 million, or $0.10 per share, and adjusted non-GAAP net income was $13.6 million, or $0.27 per share.

Amphastar Pharmaceuticals reported a net revenue of $95.9 million for Q4 2020, representing a 15% increase compared to the same period in the previous year. However, the company experienced a GAAP net loss of $6.3 million, or $0.13 per share, though adjusted non-GAAP net income was $8.0 million, or $0.16 per share.

Amphastar Pharmaceuticals reported a 4% increase in net revenues to $83.4 million for the third quarter of 2020, driven by the continued strength of Primatene Mist and the re-launch of their epinephrine vial product. GAAP net income was $3.9 million, or $0.08 per share, while adjusted non-GAAP net income was $7.6 million, or $0.15 per share.

Amphastar Pharmaceuticals reported net revenues of $85.8 million for the three months ended June 30, 2020. The company reported a GAAP net loss of $0.2 million, or $0.00 per share, and an adjusted non-GAAP net income of $7.6 million, or $0.16 per share.

Amphastar Pharmaceuticals reported a strong first quarter in 2020, with net revenues of $84.7 million and GAAP net income of $3.9 million, driven by strong sales of Primatene® Mist and hospital products.

Amphastar Pharmaceuticals reported net revenues of $83.4 million for the fourth quarter ended December 31, 2019. The company's GAAP net loss was $1.0 million, or $(0.02) per share, while adjusted non-GAAP net income was $3.6 million, or $0.07 per share.